According to the agreement, Parenteral is authorized to register, supply, and distribute Sinovac's Anflu (seasonal influenza vaccine) and Panflu.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

Parenteral intends to apply to the Drug Controller General of India for the import approval for the vaccines. The volume, delivery schedule and other specific details about how Sinovac's vaccines may be marketed and supplied to the government of India and the private market in India have not been determined.

Weidong Yin, the chairman, president and CEO of Sinovac, stated that he agreements correspond with Sinovac's international marketing strategy to partner with established local suppliers to secure regulatory approval and facilitate distribution in numerous international markets.